SEATTLE--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported data from two phase Ib clinical trials of dacetuzumab, one in combination with Rituxan® (rituximab) and Gemzar® (gemcitabine) for diffuse large B-cell lymphoma (DLBCL), and the other in combination with Revlimid® (lenalidomide) for multiple myeloma. In addition, data were reported describing a diagnostic gene signature that may identify lymphoma patients who are more likely to respond to dacetuzumab therapy. Dacetuzumab is a humanized antibody targeting CD40 that the company is developing under a worldwide collaboration agreement with Genentech, a wholly owned member of the Roche Group. The data were presented during the American Society of Hematology (ASH) 51st Annual Meeting being held in New Orleans, Louisiana.
